Fundraising Fox

Kaasim Mahmood

Investor

Partner at Advent Life Sciences

London

Writes $25K – $5M checks Β· typically $1M

About

Kaasim Mahmood joined Advent in 2005, bringing experience in clinical medicine, finance, and mergers and acquisitions. He earned an MB BS from the Royal Free and University College Medical School in London and previously worked at Cutfield, Freeman and Co, a London corporate finance firm. At Advent he has worked on direct investments and supported the legal and financial aspects of many others.

ContactΒ· self-published, not guessed

Invests in

Biotech

Experience

  1. Advent Life Sciences LLPGeneral Partnercurrent2011 β€” presentLondon Area, United Kingdom
  2. Advent Venture PartnersPrincipal2005 β€” 2012
  3. Cutfield Freeman & CoAssociate2001 β€” 2005

Investments

Board seats

F2GNerre TherapeuticsOrphalanVentus Medical

Investor

Cn CreativeKandy TherapeuticsSpeciality European Pharma

Per the firm's website.

Colleagues at Advent Life Sciences

Network4

Investors connected to Kaasim in public investor directories β€” a warm-intro map.

Frequently asked questions

Who is Kaasim Mahmood?
Kaasim Mahmood joined Advent in 2005, bringing experience in clinical medicine, finance, and mergers and acquisitions. He earned an MB BS from the Royal Free and University College Medical School in London and previously worked at Cutfield, Freeman and Co, a London corporate finance firm. At Advent he has worked on direct investments and supported the legal and financial aspects of many others.
Where does Kaasim Mahmood work?
Kaasim Mahmood is Partner at Advent Life Sciences.
What does Kaasim Mahmood invest in?
Kaasim Mahmood invests in Biotech.
What check size does Kaasim Mahmood write?
Kaasim Mahmood typically writes checks of $25K – $5M.
What boards does Kaasim Mahmood sit on?
Kaasim Mahmood holds tracked board seats at F2G, Nerre Therapeutics, Orphalan, Ventus Medical.
What companies has Kaasim Mahmood invested in?
Investments tracked here include Cn Creative, Kandy Therapeutics, Speciality European Pharma.

Shared employers